Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-blind, Placebo-controlled European Study
- 31 January 2000
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Infection
- Vol. 40 (1), 42-48
- https://doi.org/10.1053/jinf.1999.0602
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Influenza VaccinesDrugs, 1997
- French Economic Evaluations of Influenza and Influenza VaccinationPharmacoEconomics, 1996
- Amantadine and rimantadine resistance in influenza A virusesCurrent Opinion in Infectious Diseases, 1994
- 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitroAntimicrobial Agents and Chemotherapy, 1993
- Rational design of potent sialidase-based inhibitors of influenza virus replicationNature, 1993
- Selection and Characterization of a Neuraminidase-Minus Mutant of Influenza Virus and Its Rescue by Cloned Neuraminidase GenesVirology, 1993
- Amantadine for influenza A.BMJ, 1991
- Resistance of Influenza A Virus to Amantadine and Rimantadine: Results of One Decade of SurveillanceThe Journal of Infectious Diseases, 1989
- Economic impact of influenza: The individual's perspectiveAmerican Journal Of Medicine, 1987
- Influenza: Quantifying morbidity and mortalityAmerican Journal Of Medicine, 1987